Sionna Therapeutics Director Peter Thompson Sells $3.85 Million in Stock

Peter A. Thompson, serving as a director at Sionna Therapeutics, Inc. (NASDAQ: SION), has completed a substantial divestment of company shares, according to a recent filing with the Securities and Exchange Commission. The transaction, documented on a Form 4, indicates that Mr. Thompson sold 85,918 shares of common stock on July 7, 2026. The total value of the sale was approximately $3.85 million, with the securities disposed of at a price of $44.86 per share. This transaction was executed under the framework of a Rule 10b5-1 trading plan, which permits corporate insiders to establish a predetermined schedule for buying or selling shares in advance. The sale reduces Mr. Thompson's indirect holdings in Sionna Therapeutics common stock to a total of 2,469,959 shares. The securities in question were held indirectly through OrbiMed Private Investments VIII, LP. Mr. Thompson is affiliated with OrbiMed Advisors LLC, which is involved in managing the fund. He, along with OrbiMed Advisors and GP VIII, has disclaimed beneficial ownership of these securities except to the extent of any pecuniary interest. The timing of this insider sale coincides with Sionna Therapeutics trading near its 52-week high of $48.45. The stock has experienced a remarkable 110% gain over the past year, bringing the company's valuation to $1.99 billion. According to analysis by InvestingPro, the stock appears overvalued at current levels compared to its fair value estimate. This valuation perspective may provide context for the insider's decision to reduce holdings. Sionna is among the most overvalued stocks tracked by InvestingPro, which offers 11 additional ProTips for SION subscribers. In recent analyst updates, Sionna Therapeutics has been the focus of several research notes. Stifel has raised its price target for the company from $44 to $55, while maintaining a Buy rating. This adjustment follows discussions with company executives regarding the phase 2a study of SION-719. Citizens has reiterated a Market Outperform rating with a $63 price target, emphasizing the potential of Sionna's NBD1 stabilizers for cystic fibrosis treatment. Conversely, Freedom Broker has downgraded the stock to Hold from Buy, maintaining a $38 price target, citing the completion of enrollment for the SION-719 Phase 2a trial as a factor. These developments come as Sionna prepares for significant data readouts this summer. The anticipated data is expected to provide insights into its therapies compared to Vertex Pharmaceuticals standard-of-care cystic fibrosis modulators. Analysts from Citizens and Stifel have expressed confidence in the upcoming data, with Stifel particularly noting differences between Sionna's CFHBE data and Vertex's published results. The stock currently trades at $44.94, reflecting a gain of $0.94 or 2.14% during the regular session. After hours trading shows a slight decline to $44.85, representing a loss of $0.09 or 0.20%. The valuation metrics and insider activity highlight the complex dynamics surrounding Sionna Therapeutics as it approaches critical clinical milestones.